Literature DB >> 9010095

Gene amplification and proliferative kinetics in relation to prognosis of patients with gastric carcinoma.

D Amadori1, M Maltoni, A Volpi, O Nanni, E Scarpi, B Renault, N S Pellegata, M Gaudio, E Magni, G N Ranzani.   

Abstract

BACKGROUND: The differences in survival of gastric carcinoma patients who have identical clinical or pathologic stages prompted the authors to investigate the prognostic significance of biologic features that are known to affect the clinical aggressiveness of other tumor types.
METHODS: One hundred twenty-four tumor samples from patients who had received radical or palliative surgery were analyzed for c-myc, c-K-ras, hst, and c-erb B-2 gene amplification by means of the Southern blot technique. Of these tumors, 70 were also examined for cell kinetics by means of the thymidine labeling index (TLI).
RESULTS: The analysis of associations between gene amplification and the anatomicopathologic variables (TNM classification, site of tumor, and histology) showed that amplification represents a late event in the natural history of gastric carcinoma. Gene amplification showed a slight, statistically insignificant, negative impact on overall survival (OS) (P = 0.09). Amplification of c-erb B-2 correlated in a statistically significant way with reduced OS (P = 0.03). Cox multiple regression analysis revealed that neither c-erb B-2 amplification nor TLI had prognostic significance in relation to OS.
CONCLUSIONS: These data indicate that amplification of the examined oncogenes did not reveal a new independent prognostic factor for patients with gastric carcinoma. However, the authors' results did show a strong correlation between gene amplification and tumor progression, which warrants further study involving larger series of patients. At the same time, the TLI results underlined the need to identify the most suitable biologic material for use in the estimation of proliferative indexes in gastric carcinoma.

Entities:  

Mesh:

Year:  1997        PMID: 9010095     DOI: 10.1002/(sici)1097-0142(19970115)79:2<226::aid-cncr5>3.0.co;2-i

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Current status of gene therapy in gastroenterology.

Authors:  Chang-Tai Xu; Bo-Rong Pan
Journal:  World J Gastroenterol       Date:  1998-02       Impact factor: 5.742

2.  Detection of gene amplification in archival breast cancer specimens by laser-assisted microdissection and quantitative real-time polymerase chain reaction.

Authors:  U Lehmann; S Glöckner; W Kleeberger; H F von Wasielewski; H Kreipe
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

3.  Interrelationship between chromosome 8 aneuploidy, C-MYC amplification and increased expression in individuals from northern Brazil with gastric adenocarcinoma.

Authors:  Danielle-Queiroz Calcagno; Mariana-Ferreira Leal; Aline-Damaceno Seabra; Andre-Salim Khayat; Elizabeth Suchi Chen; Samia Demachki; Paulo Pimentel Assumpção; Mario Henrique Girão Faria; Silvia Helena Barem Rabenhorst; Márcia Valéria Pitombeira Ferreira; Marília de Arruda Cardoso Smith; Rommel-Rodríguez Burbano
Journal:  World J Gastroenterol       Date:  2006-10-14       Impact factor: 5.742

4.  Helicobacter pylori infection and oncogene expressions in gastric carcinoma and its precursor lesions.

Authors:  Jie Wang; David S Chi; George B Kalin; Christina Sosinski; Lou Ellen Miller; Izabela Burja; Eapen Thomas
Journal:  Dig Dis Sci       Date:  2002-01       Impact factor: 3.199

5.  Coordinate increase of telomerase activity and c-Myc expression in Helicobacter pylori-associated gastric diseases.

Authors:  Guo-Xin Zhang; Yan-Hong Gu; Zhi-Quan Zhao; Shun-Fu Xu; Hong-Ji Zhang; Hong-Di Wang; Bo Hao
Journal:  World J Gastroenterol       Date:  2004-06-15       Impact factor: 5.742

6.  c-erbB-2 is not a major factor in the development of colorectal cancer.

Authors:  J A McKay; J F Loane; V G Ross; M-M Ameyaw; G I Murray; J Cassidy; H L McLeod
Journal:  Br J Cancer       Date:  2002-02-12       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.